Trials / Completed
CompletedNCT06209970
35kDa Hyaluronan Fragment Treatment of Colorectal and Rectal Cancer
Injection of 35kDa Hyaluronan Fragment Alleviates Pain Associated With Radiotherapy for Treatment of Colorectal and Rectal Cancer
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 10 (actual)
- Sponsor
- Nakhia Impex LLC · Industry
- Sex
- All
- Age
- 48 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
HA35 (Bioactive HA or B-HA or HA35) have good tissue permeability (B-HA injection, Ministry of Health, Registration number L20200708MP07707). HA35 might not lose HA's bioactivities of binding to a variety of hyaluronan's binding proteins or receptors, including the analgesic and anticancer effects of hyaluronan, therefore being named bioactive HA or B-HA (10) (B-HA injection, Ministry of Health, Registration number L20200708MP07707).
Detailed description
The previous study has shown that naked mole rat who has high tissue content of hyaluronan and its fragments is insensitive to pain. The previous study has also shown that hyaluronan modulates pain-regulated TRPV1 channel opening, reducing peripheral nociceptor activity and pain. The previous study has again shown that local injection of 35kDa hyaluronan fragment HA35 is effective in treating inflammatory and neuropathic pain. This study employs freshly made HA35 injection for treatment of pain associated with radiotherapy for treatment of colorectal and rectal cancer. A numerical rating scale from 0 to 10 was used to assess the pain after 1 hour, 3 hours, 24 hours, 48 hours and 72 hours of the injection.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HA35 | All the freshly made HA35 or B-HA samples were diluted to a final concentration of 5 mg/ml. The filter membrane with 220nm pore size was used to filter freshly made HA35 or B-HA injection in order to test its human tissue permeability as \<220nm nino-particle. |
Timeline
- Start date
- 2023-12-20
- Primary completion
- 2024-02-01
- Completion
- 2024-03-05
- First posted
- 2024-01-18
- Last updated
- 2024-04-17
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06209970. Inclusion in this directory is not an endorsement.